F5, NXP Semiconductors and Goldman Sachs are among the movers.
Stock gainers:NXP... Here are some of the biggest movers of Tuesday, ahead of a big slate of earnings reports.Shares of F5 Inc. rallied 12% after the cloud security company beat Street estimates for the quarter.
NXP Semiconductors NV shares NXPI rose 2% after the chip maker — which gets more than half its sales from auto makers — topped Wall Street expectations ahead of a Tuesday conference call with analysts at 8 a.m. Eastern. NXP’s results come just before the earnings of another big auto supplier, Texas Instruments Inc. TXN , which reports Tuesday after the close of markets.Cadence Design Inc.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Goldman Sachs expects 'all time high' oil demand to spur large deficits, boosting pricesGoldman Sachs forecasts 'sizeable deficits' in the oil markets driving higher crude prices, especially as an 'all time high' demand for the commodity looms.
Read more »
Goldman Sachs rating cut to neutral by CitiGoldman Sachs Group was downgraded to neutral from buy at Citi, though its price target was increased to $400 from $370. Analysts led by Keith Horowitz say...
Read more »
Auto chip maker NXP tops expectations ahead of Texas Instruments earningsNXP Semiconductors NV shares rose in the extended session Monday after the chip maker topped Wall Street expectations.
Read more »
NXP forecasts third quarter above estimates on steady automotive demandChipmaker NXP Semiconductors forecast third-quarter revenue and profit above Wall Street targets on Monday, betting that demand from automakers ramping up production will cushion the hit from a weak consumer electronics market.
Read more »
These 5 stocks are on Goldman’s ‘conviction buy’ list — and it gives one more than 50% upsideA look at Goldman Sachs' 'conviction buy' stocks in recent weeks has revealed a number of names that its analysts say have serious potential.
Read more »
Goldman upgrades this biotech, sees the shares doublingThe firm's price target implies shares could rally 117%.
Read more »